The neuropeptide diazepam binding inhibitor (DBI) is an endogeneous allosteric modulator of gamma-aminobutyric acid (GABA) receptors at the benzodiazepine recognition site. Recent theories on the neurochemical cause for hepatic encephalopathy have implicated activation of inhibitory neurotransmitter GABA systems. In 20 patients with hepatic disease, blood and cerebrospinal fluid (CSF) levels of ammonia and amino acids were measured. As in previous studies there was a selective elevation of CSF amino acids as well as a correlation between CSF glutamine levels and encephalopathy. CSF DBI levels were maximally elevated 5-fold in patients with hepatic encephalopathy, but they were normal in those patients with liver disease not associated with changes in mental status and in patients with nonhepatic encephalopathy. Levels of DBI correlated with the clinical staging of hepatic encephalopathy. These data suggest that DBI may participate in the modulation of cerebral function in hepatic encephalopathy.

Rothstein, J., Mckhann, G., Guarneri, P., Barbaccia, M.l., Guidotti, A., Costa, E. (1989). Cerebrospinal fluid content of diazepam binding inhibitor in chronic hepatic encephalopathy. ANNALS OF NEUROLOGY, 26(1), 57-62 [10.1002/ana.410260109].

Cerebrospinal fluid content of diazepam binding inhibitor in chronic hepatic encephalopathy

BARBACCIA, MARIA LUISA;
1989-07-01

Abstract

The neuropeptide diazepam binding inhibitor (DBI) is an endogeneous allosteric modulator of gamma-aminobutyric acid (GABA) receptors at the benzodiazepine recognition site. Recent theories on the neurochemical cause for hepatic encephalopathy have implicated activation of inhibitory neurotransmitter GABA systems. In 20 patients with hepatic disease, blood and cerebrospinal fluid (CSF) levels of ammonia and amino acids were measured. As in previous studies there was a selective elevation of CSF amino acids as well as a correlation between CSF glutamine levels and encephalopathy. CSF DBI levels were maximally elevated 5-fold in patients with hepatic encephalopathy, but they were normal in those patients with liver disease not associated with changes in mental status and in patients with nonhepatic encephalopathy. Levels of DBI correlated with the clinical staging of hepatic encephalopathy. These data suggest that DBI may participate in the modulation of cerebral function in hepatic encephalopathy.
lug-1989
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore BIO/14 - FARMACOLOGIA
English
Con Impact Factor ISI
Diazepam Binding Inhibitor; Male; Amino Acids; Middle Aged; Female; Receptors, GABA-A; Aged; Neuropeptides; Adult; Hepatic Encephalopathy; Humans
Rothstein, J., Mckhann, G., Guarneri, P., Barbaccia, M.l., Guidotti, A., Costa, E. (1989). Cerebrospinal fluid content of diazepam binding inhibitor in chronic hepatic encephalopathy. ANNALS OF NEUROLOGY, 26(1), 57-62 [10.1002/ana.410260109].
Rothstein, J; Mckhann, G; Guarneri, P; Barbaccia, Ml; Guidotti, A; Costa, E
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/14833
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 82
  • ???jsp.display-item.citation.isi??? ND
social impact